Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Travere Therapeutics, Inc., Xencor or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Travere Therapeutics, Inc., Xencor and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Travere Therapeutics, Inc., Xencor and Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn’s disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Latest Biotechnology and Travere Therapeutics, Inc., Xencor, Inc. Stock News

As of August 20, 2026, Travere Therapeutics, Inc. had a $6.1 billion market capitalization, compared to the Biotechnology median of $286.3 million. Travere Therapeutics, Inc.’s stock is up 71.5% in 2026, up 5.5% in the previous five trading days and up 265.63% in the past year.

Currently, Travere Therapeutics, Inc. does not have a price-earnings ratio. Travere Therapeutics, Inc.’s trailing 12-month revenue is $591.3 million with a -7.4% net profit margin. Year-over-year quarterly sales growth most recently was 48.3%. Analysts expect adjusted earnings to reach $1.735 per share for the current fiscal year. Travere Therapeutics, Inc. does not currently pay a dividend.

As of August 20, 2026, Xencor, Inc. had a $2.0 billion market cap, putting it in the 53rd percentile of all stocks. Xencor, Inc.’s stock is up 79.9% in 2026, up 18% in the previous five trading days and up 255.73% in the past year.

Currently, Xencor, Inc. does not have a price-earnings ratio. Xencor, Inc.’s trailing 12-month revenue is $105.0 million with a -155.6% net profit margin. Year-over-year quarterly sales growth most recently was 17.4%. Analysts expect adjusted earnings to reach $-3.114 per share for the current fiscal year. Xencor, Inc. does not currently pay a dividend.

How We Compare Travere Therapeutics, Inc., Xencor and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Travere Therapeutics, Inc., Xencor and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Travere Therapeutics, Inc., Xencor and Inc. Stock Value Grades

Company	Ticker	Value
Travere Therapeutics, Inc.	TVTX	F
Xencor, Inc.	XNCR	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Travere Therapeutics, Inc. has a Value Score of 3, which is Ultra Expensive. Xencor, Inc. has a Value Score of 12, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Travere Therapeutics, Inc., Xencor or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Travere Therapeutics, Inc., Xencor or Inc. is the better investment when it comes to value.

Travere Therapeutics, Inc., Xencor and Inc. Growth Grades

Company	Ticker	Growth
Travere Therapeutics, Inc.	TVTX	F
Xencor, Inc.	XNCR	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Travere Therapeutics, Inc. has a Growth Score of 12, which is Very Weak. Xencor, Inc. has a Growth Score of 9, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Travere Therapeutics, Inc., Xencor or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Travere Therapeutics, Inc., Xencor or Inc. is the better investment when it comes to sustainable growth.

Travere Therapeutics, Inc., Xencor and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Travere Therapeutics, Inc.	TVTX	D
Xencor, Inc.	XNCR	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Travere Therapeutics, Inc. has a Earnings Estimate Score of 26, which is Negative. Xencor, Inc. has a Earnings Estimate Score of 67, which is Positive.

The Earnings Estimate Revisions Grade Winner: Xencor, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Xencor, Inc. has a better Earnings Estimate Revisions Grade than Travere Therapeutics, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Xencor, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Travere Therapeutics, Inc., Xencor and Inc. Grades

In addition to Growth, Value and Estimate Revisions, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Travere Therapeutics, Inc., Xencor and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Travere Therapeutics, Inc., Xencor or Inc. Stock?

Overall, Travere Therapeutics, Inc. stock has a Value Score of 3, Growth Score of 12 and Estimate Revisions Score of 26.

Xencor, Inc. stock has a Value Score of 12, Growth Score of 9 and Estimate Revisions Score of 67.

Comparing Travere Therapeutics, Inc., Xencor and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.